Combination of an Src Kinase Inhibitor with a Novel Pharmacological Antagonist of the Urokinase Receptor Diminishes in Vitro Colon Cancer Invasiveness

Clinical Cancer Research

Volumn 10, Issue 4, 2004, Pages 1545-1555

  Boyd, Douglas D ^a   Wang, Heng ^a   Avila, Hector ^a   Parikh, Nila U ^a   Kessler, Horst ^b   Magdolen, Victor ^b   Gallick, Gary E ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINO 7 TERT BUTYL 5 (4 CHLOROPHENYL)PYRAZOLO[3,4 D]PYRIMIDINE; CELL PROTEIN; NI 5.12; PLASMINOGEN ACTIVATOR; PLASMINOGEN ACTIVATOR INHIBITOR; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; UNCLASSIFIED DRUG; UROKINASE RECEPTOR;

ARTICLE; CANCER CELL CULTURE; CANCER CONTROL; CANCER INVASION; CELL ASSAY; CELL LEVEL; CELL STRAIN HT29; COLON CANCER; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DRUG TARGETING; ENZYME ACTIVITY; ENZYME ASSAY; ENZYME INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; METASTASIS; MOLECULAR WEIGHT; NORTHERN BLOTTING; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN FUNCTION; REPORTER GENE; TRANSCRIPTION REGULATION; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLOTTING, NORTHERN; BLOTTING, WESTERN; CELL LINE, TUMOR; COLLAGEN; COLONIC NEOPLASMS; DRUG COMBINATIONS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, REPORTER; HUMANS; LAMININ; NEOPLASM INVASIVENESS; PEPTIDE FRAGMENTS; PEPTIDES, CYCLIC; PROMOTER REGIONS (GENETICS); PROTEOGLYCANS; PYRIMIDINES; RECEPTORS, CELL SURFACE; SRC-FAMILY KINASES; TIME FACTORS; TRANSFECTION;

EID: 1642374708     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-1565-02     Document Type: Article

References (48)

1. r receptor protein for urokinase-type plasminogen activator. J. Biol. Chem., 263: 2358-2363, 1988.
2. Ploug, M., Ronne, E., Behrendt, N., Jensen, A., Blasi, F., and Dano, K. Cellular receptor for urokinase plasminogen activator. J. Biol. Chem., 266: 1926-1933, 1991.
3. Behrendt, N., Ploug, M., Patthy, L., Houen, G., Blasi, F., and Dano, K. The ligand-binding domain of the cell surface receptor for urokinase-type plasminogen activator. J. Biol. Chem., 266: 7842-7847, 1991.
4. Kook, Y. H., Adamski, J., Zelent, A., and Ossowski, L. The effect of antisense inhibition of urokinase receptor in human squamous cell carcinoma on malignancy. EMBO J., 13: 3983-3991, 1994.
5. Quattrone, A., Fibbi, G., Anichini, E., Pucci, M., Zamperini, A., Capaccioli, S., and Del Rosso, M. Reversion of the invasive phenotype of transformed human fibroblasts by anti-messenger oligonucleotide inhibition of urokinase receptor gene expression. Cancer Res., 55: 90-95, 1995.
6. Aguirre-Ghiso, J. A., Liu, D., Mignatti, A., Kovalski, K., and Ossowski, L. Urokinase receptor and fibronectin regulate the ERK to p38 activity ratios that determine carcinoma cell proliferation or dormancy in vivo. Mol. Biol. Cell, 12: 863-879, 2001.
7. Liu, D., Aguirre-Ghiso, J. A., Estrada, Y., and Ossowski, L. EGFR is a transducer of the urokinase receptor inititiated signal that is required for in vivo growth of a human carcinoma. Cancer Cell, 1: 445-457, 2002.
8. Ellis, V., Behrendt, N., and Dano, K. Plasminogen activation by receptor-bound urokinase. J. Biol. Chem., 266: 12752-12758, 1991.
9. Cubellis, M., Wun, T., and Blasi, F. Receptor-mediated internalization and degradation of urokinase is caused by its specific inhibitor PAI-1. EMBO J., 9: 1079-1085, 1990.
10. 2-macroglobulin receptor. J. Biol. Chem., 269: 17886-17892, 1994.
11. Wei, Y., Lukashev, M., Simon, D. I., Bodary, S. C., Rosenberg, S., Doyle, M. V., and Chapman, H. A. Regulation of integrin function by the urokinase receptor. Science (Wash. DC), 273: 1551-1555, 1996.
12. Resnati, M., Pallavicini, I., Wang, J. M., Oppenheim, J., Serhan, C. N., Romano, M., and Blasi, F. The fibrinolytic receptor for urokinase activates the G protein-coupled chemotactin receptor FPRL1/LXA4R. Proc. Natl. Acad. Sci. USA, 99: 1359-1364, 2002.
13. Nestl, A., Von Stein, O. D., Zatloukal, K., Thies, W-G., Herrlich, P., Hofmann, M., and Sleeman, J. P. Gene expression patterns associated with the metastatic phenotype in rodent and human tumors. Cancer Res., 61: 1569-1577, 2001.
14. Memarzedeh, S., Kozak, K. R., Chang, L., Natarajan, S., Shintaku, P., Reddy, S. T., and Farias-Eisner, R. Urokinase plasminogen activator receptor: prognostic biomarker for endometrial cancer. Proc. Natl. Acad. Sci. USA, 99: 10647-10652, 2002.
15. Crowley, C. W., Cohen, R., Lucas, B. K., Liu, G., Shuman, M. A., and Levinson, A. D. Prevention of metastasis by inhibition of the urokinase receptor. Proc. Natl. Acad. Sci. USA, 90: 5021-5025, 1993.
16. Mohanam, S., Chintala, S. K., Go, Y., Bhattarcharya, A., Boyd, D., and Rao, J. S. In vitro inhibition of human glioblastoma cell line invasiveness by antisense uPA receptor. Oncogene, 14: 1351-1359, 1997.
17. Mishima, K., Mazar, A., Gown, A., Skelly, M., Ji, X-D., Wang, X-D., Jones, T. R., Cavenee, W. K., and Huang, H-J. A peptide derived from the non-receptor-binding region of urokinase plasminogen activator inhibits glioblastoma growth and angiogenesis in vivo in combination with cisplatin. Proc. Natl. Acad. Sci. USA, 97: 8484-8489, 2000.
18. Rabbani, S. A., and Gladu, J. Urokinase receptor antibody can reduce tumor volume and detect the presence of occult tumor metastases in vivo. Cancer Res., 62: 2390-2397, 2002.
19. Lakka, S. S., Gondi, C. S., Yanamandra, N., Dinh, D. H., Olivero, W. C., Gujrati, M., and Rao, J. S. Synergistic down-regulation of urokinase activator receptor and matrix metalloproteinase-9 in SNB19 glioblastoma cells efficiently inhibits glioma cell invasion, angiogenesis, and tumor growth. Cancer Res., 63: 2454-2461, 2003.
20. Suzuki, S., Hayashi, Y., Wang, Y., Nakamura, T., Morita, Y., Kawasaki, K., Aoyama, N., Kim, S. R., Itoh, H., Kuroda, Y., and Doe, W. F. Urokinase type plasminogen activator receptor expression in colorectal neoplasias. Gut, 43: 798-805, 1999.
21. Ganesh, S., Sier, C. F. M., Heerding, M. M., Griffioen, G., Lamers, C. B. H., and Verspaget, H. W. Urokinase receptor and colorectal cancer survival. Lancet, 344: 401-402, 1994.
22. Abe, J., Urano, T., Konno, H., Erhan, Y., Tanaka, T., Nishino, N., Takada, A., and Nakamura, S. Larger and more invasive colorectal carcinoma contains larger amounts of plasminogen activator inhibitor type 1 and its relative ratio over urokinase receptor correlates well with tumor size. Cancer (Phila.), 86: 2602-2611, 1999.
23. Hollas, W., Blasi, F., and Boyd, D. Role of the urokinase receptor in facilitating extracellular matrix invasion by cultured colon cancer. Cancer Res., 51: 3690-3695, 1991.
24. Schlechte, W., Murano, G., and Boyd, D. D. Examination of the role of the urokinase receptor in human colon cancer mediated laminin degradation. Cancer Res., 49: 6064-6069, 1989.
25. Allgayer, H., Wang, H., Gallick, G. E., Crabtree, A., Mazar, A., Jones, T., Kraker, A. J., and Boyd, D. D. Transcriptional induction of the urokinase receptor gene by a constitutively active Src. Requirement of an upstream motif (-152/-135) bound with Sp1. J. Biol. Chem., 274: 18428-18445, 1999.
26. Allgayer, H., Boyd, D. D., Heiss, M. M., Abdalla, E. K., Curley, S. A., and Gallick, G. E. Activation of Src kinase in primary colorectal carcinoma. Cancer (Phila.), 94: 344-351, 2002.
27. Hanke, J. H., Gardner, J. P., Dow, R. L., Changelian, P. S., Brissette, W. H., Weringer, E. J., Pollok, B. A., and Connelly, P. A. Discovery of a novel, potent, and Src family-selective tyrosine kinase inhibitor. J. Biol. Chem., 271: 695-701, 1996.
28. Staley, C. A., Parikh, N. U., and Gallick, G. E. Decreased tumorigenicity of a human colon adenocarcinoma cell line by an antisense expression vector specific forr c-Src. Cell Growth Differ., 8: 269-274, 1997.
29. Boyd, D., Florent, G., Kim, P., and Brattain, M. G. Determination of the levels of urokinase and its receptor in human colon carcinoma cell lines. Cancer Res., 48: 3112-3116, 1988.
30. Boyd, D., Levine, A., Brattain, D. E., McKnight, M. K., and Brattain, M. G. Comparison of growth requirements of two human intratumoral colon carcinoma cell lines in monolayer and soft agarose. Cancer Res., 48: 2469-2474, 1988.
31. Brattain, M. G., Levine, A., Chakrabarty, S., Yeoman, L., Willson, J., and Long, B. Heterogeneity of human colon carcinoma. Cancer Metastasis Rev., 3: 177-191, 1984.
32. Boyd, D., Ziober, B., Chakrabarty, S., and Brattain, M. G. Examination of urokinase protein/transcript levels and their relationship with laminin degradation in cultured colon carcinoma. Cancer Res., 49: 816-820, 1989.
33. Allgayer, H., Wang, H., Wang, Y., Heiss, M. M., Bauer, R., Nyormoi, O., and Boyd, D. D. Transactivation of the urokinase-type plasminogen activator receptor gene through a novel promoter motif bound with an activator protein-2α-related factor. J. Biol. Chem., 274: 4702-4714, 1999.
34. c-src transforming ability by mutation of its primary sites of tyrosine phosphorylation. Cell, 49: 65-73, 1987.
35. Reiter, L. S., Kruithof, E. K., Cajot, J-F., and Sordat, B. The role of the urokinase receptor in extracellular matrix degradation by HT29 human colon carcinoma cells. Int. J. Cancer, 53: 444-450, 1993.
36. Windam, T. C., Parikh, N. U., Siwak, D. R., Summy, J. M., McConkey, D. J., Kraker, A. J., and Gallick, G. E. Src activation regulates anoikis in human tumor cell lines. Oncogene, 21: 7797-7807, 2002.
37. Schmiedeberg, N., Schmitt, M., Rolz, C., Truffault, V., Sukopp, M., Burgle, M., Wilhelm, O., Schmalix, W., Magdolen, V., and Kessler, H. Synthesis, solution structure, and biological evaluation of urokinase-type plasminogen activator (uPA)-derived receptor binding domain mimetics. J. Med. Chem., 45: 4984-4994, 2002.
38. Reuning, U., Sperl, S., Kopitz, C., Kessler, H., Kruger, A., Schmitt, M., and Magdolen, V. Urokinase-type plasminogen activator (uPA) and its receptor (uPAR): development of antagonists of uPA/uPAR interaction and their effects in vitro and in vivo. Curr. Pharm. Des., 9: 1529-1543, 2003.
39. Goodson, R. J., Doyle, M. V., Kaufman, S. E., and Rosenberg, S. High-affinity urokinase receptor antagonists identified with bacteriophage peptide display. Proc. Natl. Acad. Sci. USA, 91: 7129-7133, 1994.
40. Guo, Y., Higazi, A., Arakelian, A., Sachais, B. S., Cines, D., Goldfarb, R., Jones, T., Kwaan, H., Mazar, A., and Rabbani, S. A. A peptide derived from the nonreceptor binding region of urokinase plasminogen activator (uPA) inhibits tumor progression and angiogenesis and induces tumor cell death in vivo. FASEB J., 14: 1400-1410, 2000.
41. Guo, Y., Mazar, A., Lebrun, J., and Rabbani, S. A. An antiangiogenic urokinase-derived peptide combined with tamoxifen decreases tumor growth and metastasis in a syngenic model of breast cancer. Cancer Res., 62: 4678-4684, 2002.
42. Ploug, M., Ostergaard, S., Gardsvoll, H., Kovalski, K., Holst-Hansen, C., Holm, A., Ossowski, L., and Dano, K. Peptide-derived antagonists of the urokinase receptor. Affinity maturation by combinatorial chemistry, identification of functional epitopes, and inhibitory effect on cancer cell intravasation. Biochemistry, 40: 12157-12168, 2001.
43. Wilhelm, O., Weidle, U., Rettenberger, S., Schmitt, M., and Graeff, H. Recombinant soluble urokinase receptor as a scavenger for urokinase-type plasminogen activator (uPA). Inhibition of proliferation and invasion of human ovarian cancer cells. FEBS Lett., 337: 131-134, 1994.
44. Zannetti, A., Del Vecchio, S., Carrieto, M. V., Fonti, R., Franco, P., Botti, G., D'Aiuto, G., Stoppelli, M. P., and Salvatore, M. Coordinate up-regulation of Sp1 DNA-binding activity and urokinase receptor expression in breast carcinoma. Cancer Res., 60: 1546-1551, 2000.
45. Bell, S., Brackenbury, R. W., Leslie, N. D., and Degen, J. L. Plasminogen activator gene expression is induced by the src oncogene product and tumor promoters. J. Biol. Chem., 265: 1333-1338, 1990.
46. Sato, H., Kita, M., and Seiki, M. v-src activates the expression of 92-kDa type IV collagenase through the AP-1 site and the GT box homologous to retinoblastoma control elements. J. Biol. Chem., 268: 23460-23468, 1993.
47. Ellis, L. M., Staley, C. A., Liu, W., Fleming, R. Y. D., Parikh, N. U., Bucana, C. D., and Gallick, G. E. Down-regulation of vascular endothelial growth factor in a human colon carcinoma cell line transfected with an aintisense expression vector specific for c-src. J. Biol. Chem., 273: 1052-1057, 1998.
48. Cao, W., Luttrel, L. M., Medvedev, A. V., Pierce, K. L., Daniel, K. W., Dixon, T. M., Lefkowitz, R. J., and Collins, S. Direct binding of activated c-Src to the β3-adrenergic receptor is required for MAP kinase activation. J. Biol. Chem., 275: 38131-38134, 2000.